NCT02470585 · BASELINE

Baseline characteristics

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · Source last updated 2024-10-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants

groups

description
Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve \[AUC\] of 6 mg per milliliter per minute (mg/mL/min), every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles. Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.
id
BG000
title
Placebo + Carboplatin + Paclitaxel -> Placebo
description
Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks, and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles. Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.
id
BG001
title
Veliparib + Carboplatin + Paclitaxel -> Placebo
description
Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks, and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles. Participants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.
id
BG002
title
Veliparib + Carboplatin + Paclitaxel -> Veliparib
description
Total of all reporting groups
id
BG003
title
Total

measures

classes
categories
measurements
group Id
BG000
lower Limit
33.0
upper Limit
86.0
value
62.0
group Id
BG001
lower Limit
22.0
upper Limit
88.0
value
62.0
group Id
BG002
lower Limit
30.0
upper Limit
85.0
value
62.0
group Id
BG003
lower Limit
22.0
upper Limit
88.0
value
62.0
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
dispersion Type
FULL_RANGE
param Type
MEDIAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
233
group Id
BG001
value
226
group Id
BG002
value
228
group Id
BG003
value
687
title
< 65 years
measurements
group Id
BG000
value
142
group Id
BG001
value
157
group Id
BG002
value
154
group Id
BG003
value
453
title
≥ 65 years
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
param Type
COUNT_OF_PARTICIPANTS
title
Age, Customized
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
title
Female
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
0
title
Male
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
28
group Id
BG001
value
27
group Id
BG002
value
26
group Id
BG003
value
81
title
Hispanic or Latino
measurements
group Id
BG000
value
347
group Id
BG001
value
356
group Id
BG002
value
356
group Id
BG003
value
1059
title
Not Hispanic or Latino
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
0
title
Unknown or Not Reported
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
param Type
COUNT_OF_PARTICIPANTS
title
Ethnicity (NIH/OMB)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
299
group Id
BG001
value
297
group Id
BG002
value
300
group Id
BG003
value
896
title
White
measurements
group Id
BG000
value
10
group Id
BG001
value
13
group Id
BG002
value
20
group Id
BG003
value
43
title
Black or African American
measurements
group Id
BG000
value
59
group Id
BG001
value
69
group Id
BG002
value
56
group Id
BG003
value
184
title
Asian
measurements
group Id
BG000
value
1
group Id
BG001
value
1
group Id
BG002
value
1
group Id
BG003
value
3
title
American Indian or Alaska Native
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
2
group Id
BG003
value
3
title
Native Hawaiian or other Pacific Islander
measurements
group Id
BG000
value
3
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
3
title
Multi-race
measurements
group Id
BG000
value
2
group Id
BG001
value
3
group Id
BG002
value
3
group Id
BG003
value
8
title
Missing
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
param Type
COUNT_OF_PARTICIPANTS
title
Race/Ethnicity, Customized
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
266
group Id
BG001
value
261
group Id
BG002
value
267
group Id
BG003
value
794
title
North America
measurements
group Id
BG000
value
23
group Id
BG001
value
30
group Id
BG002
value
25
group Id
BG003
value
78
title
Japan
measurements
group Id
BG000
value
86
group Id
BG001
value
92
group Id
BG002
value
90
group Id
BG003
value
268
title
Rest of World
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
param Type
COUNT_OF_PARTICIPANTS
title
Geographic Region
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
92
group Id
BG001
value
98
group Id
BG002
value
108
group Id
BG003
value
298
title
Germline or tissue BRCA1/2 mutation
measurements
group Id
BG000
value
254
group Id
BG001
value
243
group Id
BG002
value
245
group Id
BG003
value
742
title
Germline or tissue BRCA1/2 wildtype
measurements
group Id
BG000
value
29
group Id
BG001
value
42
group Id
BG002
value
29
group Id
BG003
value
100
title
Missing
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
description
The BRCA-mutation cohort was defined as participants who had deleterious or suspected deleterious germline (gBRCA) or tissue-based (tBRCA) mutations as determined by the Myriad BRACAnalysis® companion diagnostic (CDx) or myChoice® HRD CDx assay, respectively, in BRCA1 or BRCA2.
param Type
COUNT_OF_PARTICIPANTS
title
BRCA-Deficient Status
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
207
group Id
BG001
value
206
group Id
BG002
value
214
group Id
BG003
value
627
title
HRD
measurements
group Id
BG000
value
124
group Id
BG001
value
123
group Id
BG002
value
125
group Id
BG003
value
372
title
Non-HRD
measurements
group Id
BG000
value
44
group Id
BG001
value
54
group Id
BG002
value
43
group Id
BG003
value
141
title
Missing
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
description
The HRD cohort consisted of participants who had tumors that were BRCA-mutated or had HRD according to the Myriad myChoice® assay, on which a score of ≥ 33 was considered to indicate HRD status, and a score of \< 33 was considered to indicate non-HRD status.
param Type
COUNT_OF_PARTICIPANTS
title
Homologous Recombination Deficiency (HRD) Status
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
292
group Id
BG001
value
288
group Id
BG002
value
295
group Id
BG003
value
875
title
Stage III
measurements
group Id
BG000
value
82
group Id
BG001
value
94
group Id
BG002
value
87
group Id
BG003
value
263
title
Stage IV
measurements
group Id
BG000
value
1
group Id
BG001
value
1
group Id
BG002
value
0
group Id
BG003
value
2
title
Missing
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
description
Staging of primary ovarian carcinomas according to the International Federation of Gynecology and Obstetrics (FIGO) criteria, based on clinical examination, surgical exploration, histologic characteristics and cytologic testing. STAGE III: Tumor involves 1 or both ovaries with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastases to the retroperitoneal lymph nodes. STAGE IV: Distant metastases excluding peritoneal metastases
param Type
COUNT_OF_PARTICIPANTS
title
Stage of Disease
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
250
group Id
BG001
value
253
group Id
BG002
value
261
group Id
BG003
value
764
title
Primary
measurements
group Id
BG000
value
107
group Id
BG001
value
114
group Id
BG002
value
99
group Id
BG003
value
320
title
Interval
measurements
group Id
BG000
value
18
group Id
BG001
value
16
group Id
BG002
value
22
group Id
BG003
value
56
title
No surgery received
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
description
Cytoreductive surgery could be performed before randomization and the initiation of study treatment (primary) or after 3 cycles of study treatment (interval), determined at the discretion of the investigator.
param Type
COUNT_OF_PARTICIPANTS
title
Type of Surgery Received
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
116
group Id
BG001
value
118
group Id
BG002
value
124
group Id
BG003
value
358
title
No residual disease
measurements
group Id
BG000
value
58
group Id
BG001
value
46
group Id
BG002
value
54
group Id
BG003
value
158
title
Microscopic residual disease only
measurements
group Id
BG000
value
76
group Id
BG001
value
89
group Id
BG002
value
83
group Id
BG003
value
248
title
Any macroscopic residual disease
denoms
counts
group Id
BG000
value
250
group Id
BG001
value
253
group Id
BG002
value
261
group Id
BG003
value
764
units
Participants
description
Data were collected after interval surgery after cycle 3.
param Type
COUNT_OF_PARTICIPANTS
population Description
Participants who underwent primary surgery
title
Residual Disease After Primary Surgery
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
50
group Id
BG001
value
46
group Id
BG002
value
45
group Id
BG003
value
141
title
No residual disease
measurements
group Id
BG000
value
22
group Id
BG001
value
30
group Id
BG002
value
24
group Id
BG003
value
76
title
Microscopic residual disease only
measurements
group Id
BG000
value
31
group Id
BG001
value
34
group Id
BG002
value
27
group Id
BG003
value
92
title
Any macroscopic residual disease
measurements
group Id
BG000
value
4
group Id
BG001
value
4
group Id
BG002
value
3
group Id
BG003
value
11
title
Missing
denoms
counts
group Id
BG000
value
107
group Id
BG001
value
114
group Id
BG002
value
99
group Id
BG003
value
320
units
Participants
param Type
COUNT_OF_PARTICIPANTS
population Description
Participants who underwent interval surgery
title
Residual Disease After Interval Surgery
unit Of Measure
Participants

population Description

The intention-to-treat (ITT) population consisted of all randomized participants.

Complete source fields

denoms

counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants

groups

description
Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve \[AUC\] of 6 mg per milliliter per minute (mg/mL/min), every 3 weeks, and paclitaxel 175 mg per square meter (mg/m²) of body-surface area (BSA), administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles. Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.
id
BG000
title
Placebo + Carboplatin + Paclitaxel -> Placebo
description
Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks, and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles. Participants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.
id
BG001
title
Veliparib + Carboplatin + Paclitaxel -> Placebo
description
Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg/mL/min every 3 weeks, and paclitaxel 175 mg/m² of BSA administered every 3 weeks, or 80 mg/m² administered weekly, for six 21-day cycles. Participants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.
id
BG002
title
Veliparib + Carboplatin + Paclitaxel -> Veliparib
description
Total of all reporting groups
id
BG003
title
Total

measures

classes
categories
measurements
group Id
BG000
lower Limit
33.0
upper Limit
86.0
value
62.0
group Id
BG001
lower Limit
22.0
upper Limit
88.0
value
62.0
group Id
BG002
lower Limit
30.0
upper Limit
85.0
value
62.0
group Id
BG003
lower Limit
22.0
upper Limit
88.0
value
62.0
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
dispersion Type
FULL_RANGE
param Type
MEDIAN
title
Age, Continuous
unit Of Measure
years
classes
categories
measurements
group Id
BG000
value
233
group Id
BG001
value
226
group Id
BG002
value
228
group Id
BG003
value
687
title
< 65 years
measurements
group Id
BG000
value
142
group Id
BG001
value
157
group Id
BG002
value
154
group Id
BG003
value
453
title
≥ 65 years
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
param Type
COUNT_OF_PARTICIPANTS
title
Age, Customized
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
title
Female
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
0
title
Male
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
28
group Id
BG001
value
27
group Id
BG002
value
26
group Id
BG003
value
81
title
Hispanic or Latino
measurements
group Id
BG000
value
347
group Id
BG001
value
356
group Id
BG002
value
356
group Id
BG003
value
1059
title
Not Hispanic or Latino
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
0
title
Unknown or Not Reported
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
param Type
COUNT_OF_PARTICIPANTS
title
Ethnicity (NIH/OMB)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
299
group Id
BG001
value
297
group Id
BG002
value
300
group Id
BG003
value
896
title
White
measurements
group Id
BG000
value
10
group Id
BG001
value
13
group Id
BG002
value
20
group Id
BG003
value
43
title
Black or African American
measurements
group Id
BG000
value
59
group Id
BG001
value
69
group Id
BG002
value
56
group Id
BG003
value
184
title
Asian
measurements
group Id
BG000
value
1
group Id
BG001
value
1
group Id
BG002
value
1
group Id
BG003
value
3
title
American Indian or Alaska Native
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
2
group Id
BG003
value
3
title
Native Hawaiian or other Pacific Islander
measurements
group Id
BG000
value
3
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
3
title
Multi-race
measurements
group Id
BG000
value
2
group Id
BG001
value
3
group Id
BG002
value
3
group Id
BG003
value
8
title
Missing
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
param Type
COUNT_OF_PARTICIPANTS
title
Race/Ethnicity, Customized
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
266
group Id
BG001
value
261
group Id
BG002
value
267
group Id
BG003
value
794
title
North America
measurements
group Id
BG000
value
23
group Id
BG001
value
30
group Id
BG002
value
25
group Id
BG003
value
78
title
Japan
measurements
group Id
BG000
value
86
group Id
BG001
value
92
group Id
BG002
value
90
group Id
BG003
value
268
title
Rest of World
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
param Type
COUNT_OF_PARTICIPANTS
title
Geographic Region
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
92
group Id
BG001
value
98
group Id
BG002
value
108
group Id
BG003
value
298
title
Germline or tissue BRCA1/2 mutation
measurements
group Id
BG000
value
254
group Id
BG001
value
243
group Id
BG002
value
245
group Id
BG003
value
742
title
Germline or tissue BRCA1/2 wildtype
measurements
group Id
BG000
value
29
group Id
BG001
value
42
group Id
BG002
value
29
group Id
BG003
value
100
title
Missing
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
description
The BRCA-mutation cohort was defined as participants who had deleterious or suspected deleterious germline (gBRCA) or tissue-based (tBRCA) mutations as determined by the Myriad BRACAnalysis® companion diagnostic (CDx) or myChoice® HRD CDx assay, respectively, in BRCA1 or BRCA2.
param Type
COUNT_OF_PARTICIPANTS
title
BRCA-Deficient Status
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
207
group Id
BG001
value
206
group Id
BG002
value
214
group Id
BG003
value
627
title
HRD
measurements
group Id
BG000
value
124
group Id
BG001
value
123
group Id
BG002
value
125
group Id
BG003
value
372
title
Non-HRD
measurements
group Id
BG000
value
44
group Id
BG001
value
54
group Id
BG002
value
43
group Id
BG003
value
141
title
Missing
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
description
The HRD cohort consisted of participants who had tumors that were BRCA-mutated or had HRD according to the Myriad myChoice® assay, on which a score of ≥ 33 was considered to indicate HRD status, and a score of \< 33 was considered to indicate non-HRD status.
param Type
COUNT_OF_PARTICIPANTS
title
Homologous Recombination Deficiency (HRD) Status
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
292
group Id
BG001
value
288
group Id
BG002
value
295
group Id
BG003
value
875
title
Stage III
measurements
group Id
BG000
value
82
group Id
BG001
value
94
group Id
BG002
value
87
group Id
BG003
value
263
title
Stage IV
measurements
group Id
BG000
value
1
group Id
BG001
value
1
group Id
BG002
value
0
group Id
BG003
value
2
title
Missing
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
description
Staging of primary ovarian carcinomas according to the International Federation of Gynecology and Obstetrics (FIGO) criteria, based on clinical examination, surgical exploration, histologic characteristics and cytologic testing. STAGE III: Tumor involves 1 or both ovaries with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastases to the retroperitoneal lymph nodes. STAGE IV: Distant metastases excluding peritoneal metastases
param Type
COUNT_OF_PARTICIPANTS
title
Stage of Disease
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
250
group Id
BG001
value
253
group Id
BG002
value
261
group Id
BG003
value
764
title
Primary
measurements
group Id
BG000
value
107
group Id
BG001
value
114
group Id
BG002
value
99
group Id
BG003
value
320
title
Interval
measurements
group Id
BG000
value
18
group Id
BG001
value
16
group Id
BG002
value
22
group Id
BG003
value
56
title
No surgery received
denoms
counts
group Id
BG000
value
375
group Id
BG001
value
383
group Id
BG002
value
382
group Id
BG003
value
1140
units
Participants
description
Cytoreductive surgery could be performed before randomization and the initiation of study treatment (primary) or after 3 cycles of study treatment (interval), determined at the discretion of the investigator.
param Type
COUNT_OF_PARTICIPANTS
title
Type of Surgery Received
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
116
group Id
BG001
value
118
group Id
BG002
value
124
group Id
BG003
value
358
title
No residual disease
measurements
group Id
BG000
value
58
group Id
BG001
value
46
group Id
BG002
value
54
group Id
BG003
value
158
title
Microscopic residual disease only
measurements
group Id
BG000
value
76
group Id
BG001
value
89
group Id
BG002
value
83
group Id
BG003
value
248
title
Any macroscopic residual disease
denoms
counts
group Id
BG000
value
250
group Id
BG001
value
253
group Id
BG002
value
261
group Id
BG003
value
764
units
Participants
description
Data were collected after interval surgery after cycle 3.
param Type
COUNT_OF_PARTICIPANTS
population Description
Participants who underwent primary surgery
title
Residual Disease After Primary Surgery
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
50
group Id
BG001
value
46
group Id
BG002
value
45
group Id
BG003
value
141
title
No residual disease
measurements
group Id
BG000
value
22
group Id
BG001
value
30
group Id
BG002
value
24
group Id
BG003
value
76
title
Microscopic residual disease only
measurements
group Id
BG000
value
31
group Id
BG001
value
34
group Id
BG002
value
27
group Id
BG003
value
92
title
Any macroscopic residual disease
measurements
group Id
BG000
value
4
group Id
BG001
value
4
group Id
BG002
value
3
group Id
BG003
value
11
title
Missing
denoms
counts
group Id
BG000
value
107
group Id
BG001
value
114
group Id
BG002
value
99
group Id
BG003
value
320
units
Participants
param Type
COUNT_OF_PARTICIPANTS
population Description
Participants who underwent interval surgery
title
Residual Disease After Interval Surgery
unit Of Measure
Participants

population Description

The intention-to-treat (ITT) population consisted of all randomized participants.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice